LongevityNext / Trials
Source-reviewed evidence, findings and limitations. Research intelligence, not treatment recommendations.
34 eligible records
Source-reviewed intelligence
Automatically included source-reviewed records; inclusion is not an editorial endorsement.
Evidence reviewed
ASPREE compared aspirin 100 mg daily with placebo in 19,114 independent older adults. Over a median 4.7 years, the main disability-free survival outcome did not significantly improve, while major bleeding was more frequent. ASPREE-XT follows the same parent trial; later medication use was not continuously randomized.
Boundary: Main combined outcome not significantly improved; no individual stopping conclusion.
Evidence reviewed
JUPITER compared rosuvastatin 20 mg daily with placebo. This exploratory report concerns 5,695 participants aged 70 or older without cardiovascular disease, with LDL cholesterol below 130 mg/dL and elevated hsCRP (at least 2 mg/L). Fewer combined vascular events were reported; the mortality estimate remained uncertain.
Boundary: Exploratory subgroup with a selected inflammatory-risk profile; mortality remains uncertain.
Evidence reviewed
PROSPER compared pravastatin 40 mg daily with placebo in 5,804 adults aged 70-82 with previous vascular disease or risk factors, followed for an average of 3.2 years. Fewer combined vascular events were reported; the mixed population limits application to healthy older adults.
Boundary: Mixed prevention population; the overall estimate is not a primary-prevention-only result.
Evidence reviewed
Clarity AD: CLARITY AD showed less average cognitive-functional decline with lecanemab over 18 months, not recovery, with material ARIA and infusion-reaction risks.
Boundary: Both groups worsened; an 18-month randomized comparison does not demonstrate causal long-term extension benefit.
Evidence reviewed
DO-HEALTH: DO-HEALTH's selected methylation substudy found small omega-3-related changes in PhenoAge, GrimAge2 and DunedinPACE, not proof of clinical rejuvenation or lifespan gain.
Boundary: Clock response does not establish lifespan extension or whole-body rejuvenation.
Evidence reviewed
SELECT: SELECT demonstrated fewer major cardiovascular events with semaglutide in adults with established cardiovascular disease and overweight/obesity without diabetes, alongside greater treatment discontinuation.
Boundary: A secondary composite including macroalbuminuria is not proof of preventing kidney failure in all populations.
Source-reviewed intelligence
Directly related records lead this section.
Evidence reviewed
A small randomized crossover mechanistic study in older adults with impaired glucose tolerance.
Boundary: Not clinical longevity-outcome, treatment, prevention or dosing evidence.
Evidence reviewed
A role-based framework for reading trial endpoints, estimands, multiplicity, clinical meaning and surrogate claims.
Boundary: Endpoint labels alone do not establish confirmatory force or clinical importance.
Evidence reviewed
Tracks TAME's proposed design, composite endpoint, funding, registration and launch status without treating plans as results.
Boundary: Design and status are not results; metformin is not established as an anti-aging treatment.
Source-reviewed intelligence
Additional directly related records follow the section-specific lead set.
Evidence reviewed
Separates DO-HEALTH's null primary clinical endpoint family from a later small post hoc DNA-methylation signal.
Boundary: Clock changes are not proof of slower clinical aging, healthspan or lifespan.
Evidence reviewed
A claim-to-evidence framework separating exposure, target engagement, biomarker movement, safety and clinical benefit.
Boundary: Interpretive context does not establish that an intervention works.
Evidence reviewed
The aging Hallmarks are an influential research framework, not a complete causal theory, treatment checklist or validated endpoint set.
Boundary: Framework context does not validate an intervention, biomarker or clinical endpoint.
Evidence reviewed
Company-and-pipeline intelligence separating company reports, registry facts and unavailable clinical outcomes.
Boundary: Pipeline and source mapping, not clinical validation or investment analysis.
Evidence reviewed
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
Evidence reviewed
Separates molecule-specific clinical outcomes from observational, mechanistic and direct longevity claims.
Boundary: Benefits in indicated high-risk populations do not establish direct slowing of aging or lifespan extension in generally healthy people.
Evidence reviewed
Tracks human senolytic evidence, registered programs, negative translation and preclinical limits.
Boundary: Early proof of biology and model clearance do not establish human rejuvenation, generalized healthspan or lifespan extension.
LN Pro preview